TWOEquity · Weekly research terminal

4160

Genetics Generation Advancement Corp.

TW Healthcare Diagnostics & Research

Latest week
14 Aug 2026
Weekly close
39.80 TWD
Fair value
55.59 TWD
Next-week expectancy
Negative 36.25%
Sharemaestro
Weekly Chart Pack Completed weekly market data · Independent research

TWO · Equity · Taiwan

4160

Genetics Generation Advancement Corp.

Healthcare Diagnostics & Research

Genetics Generation Advancement Corp. engages in the development and implementation of digital data management systems for gene testing, biological, chemical, and materials information in Taiwan. The company offers testing services, such as pre-implantation, prenatal stage, newborn medical examination, health management, reproductive medicine testing, obstetrics and gynecology, neonatology and pediatrics, oncology, and medical research services. It also provides AI and data applications, such as bioinformatic, materials sciences, research and development management, enterprise quality …

Last updated
14 Aug 2026
Exchange
Taipei Exchange · TWO
Sector
Healthcare
Industry
Diagnostics & Research
Currency
TWD
Market capitalisation
1,062,275,200
Fair value reference
55.59
Next-week expectancy
Negative · 36.25%

Over the latest 12 completed weeks ending 2026-08-14, 4160 fell 0.25%, moving from 39.90 to 39.80. The latest weekly close is below the Trend Line and below Fair Value. Trend Signal is inactive on the latest week and was active in 0 of the last 12 weeks. Relative Strength is -41.99 and has improved across the 12-week window. Market Dynamics is -0.09 on the latest week. Next-week expectancy is negative at 36.25% based on similar historical setup states.

Week Ending
14 Aug 2026
Latest Close
39.80
12-Week Change
-0.25%
Trend Signal
Inactive
Next-Week Expectancy
Negative 36.25%
Signal Weeks
0 of 12

Weekly Price

Weekly Close Trend Line Fair Value Activity Lines

Chart Panels

Choose up to 5 panels. Drag panel headers to reorder.

Chart Summary

Key Points

Week Ending
14 Aug 2026
Latest Close
39.80
12-Week Change
-0.25%
Trend Signal
Inactive
Next-Week Expectancy
Negative 36.25%
Signal Weeks
0 of 12
Vs Trend Line
Below
Vs Fair Value
Below
Relative Strength
-41.99
Market Dynamics
-0.09

Over the latest 12 completed weeks ending 2026-08-14, 4160 fell 0.25%, moving from 39.90 to 39.80. The latest weekly close is below the Trend Line and below Fair Value. Trend Signal is inactive on the latest week and was active in 0 of the last 12 weeks. Relative Strength is -41.99 and has improved across the 12-week window. Market Dynamics is -0.09 on the latest week. Next-week expectancy is negative at 36.25% based on similar historical setup states.

Industry Peers

Taiwan equities in Diagnostics & Research

Stock Exchange Week Open High Low Close Change
6847 Puriblood Medical Co., Ltd. TWO 14 Aug 2026 77.70 81.40 75.80 79.30 2.06%
6939 TFBS Bioscience Inc. TWO 14 Aug 2026 19.50 20.00 18.70 19.65 0.77%
7595 Pharmigene, Inc. TWO 14 Aug 2026 7.20 7.36 6.90 7.25 0.69%
1784 BIONET Corp. TWO 14 Aug 2026 60.20 62.90 60.20 60.60 0.66%
6615 Sofiva Genomics Co.,Ltd. TWO 14 Aug 2026 34.20 34.60 33.45 33.75 -1.32%
4153 DIVA Laboratories, Ltd. TWO 14 Aug 2026 33.45 33.45 32.40 33.00 -1.35%
6645 Kim Forest Enterprise Co., Ltd. TAI 14 Aug 2026 13.55 13.60 13.10 13.25 -2.21%
6661 Welgene Biotech Co.,Ltd. TWO 14 Aug 2026 17.60 17.60 16.00 16.75 -4.83%

Next-week expectancy

Next-week expectancy is a short-term historical read. It compares the latest completed-week setup with broadly similar past setups and asks whether the following week tended to close higher or lower.

It is not a trend call, a price target, or a guarantee. A positive read can appear while price is below trend or activity pressure is weak, because it is measuring short-term follow-through odds for the current setup state.

Use it as one context layer beside Trend Line, Relative Strength, Market Dynamics, Fair Value, and the visible price structure.

Evidence context